Atlas Trials

A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

Clinical trial NCT04744207 · COMPLETED

Trial details

NCT number
NCT04744207
Sponsor
Gesynta Pharma AB
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Systemic Sclerosis
Start date
2020-12-29
Primary completion
2022-06-15
Enrollment
94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.